Health Care [ 4/12 ] | Pharmaceuticals [ 8/75 ]
NASDAQ | Common Stock
BioAge Labs, Inc. is a biopharmaceutical company that develops therapeutic product candidates for metabolic diseases.
The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.
It also provides azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults.
It develops BGE-102, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation.
The company was incorporated in 2015 and is based in Richmond, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 6, 25 | -0.56 Increased by +91.64% | -0.51 Decreased by -9.01% |
| Aug 6, 25 | -0.60 Increased by 0.00% | -0.38 Decreased by -57.32% |
| May 6, 25 | -0.36 Decreased by -140.00% | -0.53 Increased by +31.77% |
| Mar 20, 25 | -1.00 Decreased by -400.00% | -0.66 Decreased by -52.67% |
| Nov 7, 24 | -6.70 Decreased by -2.06 K% | -0.73 Decreased by -812.43% |
| Aug 28, 24 | -0.60 Decreased by -71.43% | - |
| Dec 31, 17 | -0.15 Increased by +28.57% | -0.18 Increased by +16.67% |
| Jun 30, 17 | -0.20 | -0.13 Decreased by -53.85% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 2.05 M Increased by +N/A% | -20.17 M Increased by +13.82% | Decreased by -982.04% Decreased by N/A% |
| Jun 30, 25 | 2.41 M Increased by +N/A% | -21.56 M Decreased by -58.77% | Decreased by -893.99% Decreased by N/A% |
| Mar 31, 25 | 1.45 M Increased by +N/A% | -12.93 M Increased by +0.49% | Decreased by -890.97% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by N/A% | -21.13 M Decreased by -0.82% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -23.41 M Decreased by -60.05% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -13.58 M Increased by +20.98% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -12.99 M Decreased by -17.21% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by -100.00% | -20.96 M Increased by +79.47% | Decreased by N/A% Decreased by N/A% |